Submit Content
Get the latest delivered to your inbox
Privacy Policy

BD Releases 2015 Sustainability Performance Update Report

Published 09-22-16

Issued by BD - Becton, Dickinson and Company


BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has published its 2015 Sustainability Performance Update report.

Report Highlights

BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, has published its 2015 Sustainability Performance Update report.

The report provides an update of BD’s global environmental, social and governance performance, against the company’s 2020 Sustainability goals, providing progress one year after the goals were announced. In addition to an ongoing focus on improving environmental performance, BD’s sustainability strategy takes a broad view of the Company’s role in addressing global societal issues in four strategic areas:

  • Innovation – health care safety, reach and cost
  • Access – health care in resource-limited populations
  • Efficiency – environmentally sound products and resilient operations
  • Empowerment – positive workforce and community impacts.

Highlights from the 2015 report include

  • Creating end-to-end solutions across the care continuum and repositioning BD as a global leader in medication management and healthcare safety solutions with the $12 billion acquisition of CareFusion. BD also entered the genomics space with the acquisitions of GenCell Biosystems and Cellular Research.
  • The application of BD’s technology, resources and people to help address the world’s more pressing health challenges. The BD-PEPFAR public-private partnership continues to enable improvements to the quality of diagnostics across six countries. More than 120 associates have been deployed to serve as part of the program.
  • Progress against goals to reduce emissions, water and energy consumption and waste generation, including a 59 percent decrease in greenhouse gas emissions from operations.  
  • How BD’s associates around the world are able to make a difference in the lives of others. BD’s Volunteer Service Trip program reached a 10-year milestone in 2015, deploying more than 150 associate volunteers from 68 BD sites to participate in 16 trips, since the program’s inception.

About BD
BD is a global medical technology company that is advancing the world of health by improving medical discovery, diagnostics and the delivery of care. BD leads in patient and health care worker safety and the technologies that enable medical research and clinical laboratories. The company provides innovative solutions that help advance medical research and genomics, enhance the diagnosis of infectious disease and cancer, improve medication management, promote infection prevention, equip surgical and interventional procedures, optimize respiratory care and support the management of diabetes. The company partners with organizations around the world to address some of the most challenging global health issues. BD has more than 45,000 associates across 50 countries who work in close collaboration with customers and partners to help enhance outcomes, lower health care delivery costs, increase efficiencies, improve health care safety and expand access to health. For more information on BD, please visit

BD - Becton, Dickinson and Company

BD - Becton, Dickinson and Company

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people's health throughout the world. BD is focused on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases, and advancing research and discovery of new drugs and vaccines. The Company's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 28,000 people in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, industry and the general public.

Join today and get the latest delivered to your inbox